Login to Your Account

CV Therapeutics Privately Sells $100 Million In Convertible Notes

By Brady Huggett

Monday, June 16, 2003
CV Therapeutics Inc., adding to a line of biotech companies seeking (and getting) funding through debt financings, agreed to sell $100 million aggregate principal amount of 2 percent senior subordinated convertible debentures. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription